Objective Epidemiologic estimates for age of systemic lupus erythematosus (SLE) diagnosis are limited, particularly for men and racial and ethnic subpopulations in the United States. Leveraging the .....

Introduction Avacopan, an oral C5a receptor inhibitor, approved for ANCA-associated vasculitis (AAV) in 2021. Following FDA reports of 76 worldwide drug induced liver injury (DILI) cases (66 in Japa.....

Objective The Navajo Nation, the largest Native American reservation, faces a high prevalence of rheumatoid arthritis (RA) and a critical shortage of rheumatology providers. To address this gap, we ...

Jeff Goldsmith reviews “A Giant Leap,” a thoughtful new book about how artificial intelligence is transforming health care, by Robert Wachter.

Purpose of review This update examines the current policy landscape for biosimilars, particularly those approved for treating rheumatoid arthritis. We review recent literature and recommend policies t...

The coming decade might see major cuts to US Government funding for biomedicine and the mainstreaming of pseudoscience. This Perspective highlights how your biosciences PhD gives you the problem-solvi...

Background Systemic lupus erythematosus (SLE) has numerous symptoms across organs and an unpredictable flare-remittance pattern. This has made it challenging to understand drivers of long-term SLE out...

This randomized clinical trial investigates whether early application of mycophenolate mofetil improves long-term outcomes in patients with newly diagnosed systemic lupus erythematosus with a high tit...

WASHINGTON — Disparities in the use of biologic and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis, including among older, Black and Asian patients, have not c...